Clinical trials: Cancer Recurrence
Relapsed Acute Lymphoblastic Leukemia, Relapsed Acute Myelogenous Leukemia
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
This is a phase I trial of an investigational drug called GNKG168 in patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) who are in morphologic remission but are positive…
- Trial name
- NCT01743807
- Testing
- GNKG168
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Carcinoma, Renal Cell
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have…
- Trial name
- CheckMate 914 (NCT03138512)
- Testing
- nivolumab, ipilimumab
- Where
- 200 sites in United States, Argentina and 23 more
- Volunteers
- 1,641 people
- Sponsor
- Bristol-Myers Squibb
Relapsed/Refractory Aggressive B-Cell Malignancies
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy, ONCT-808, in patients with relapsed/refractory (R/R) aggressive B cell malignancies.
- Trial name
- NCT05588440
- Testing
- ONCT-808, Bridging Therapy
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Oncternal Therapeutics, Inc
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Biochemical Recurrence of Malignant Neoplasm of Prostate
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of…
- Trial name
- COBRA (NCT05249127)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Relapsed or Refractory Multiple Myeloma
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT02099539
- Testing
- N-803
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Altor BioScience
Advanced Cancer, Relapsed Cancer
Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents
This study will evaluate the effects of human-animal interaction on reducing anxiety, depression, worry, and pain and enhancing quality of life in children ages 6-17 years old with a life threatening cancer and their parent…
- Conditions
- Advanced Cancer, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT04310345
- Testing
- Animal-Assisted Interactions
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Relapsed or Refractory Multiple Myeloma
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and…
- Trial name
- ARROW2 (NCT03859427)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 108 sites in United States, Austria and 15 more
- Volunteers
- 454 people
- Sponsor
- Amgen
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have…
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma
- Trial name
- NCT02595866
- Testing
- Antiretroviral Therapy, Biopsy, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
This clinical study will assess the safety and tolerability of escalating doses of mRNA-2416 alone and in combination with administered fixed doses of durvalumab in participants with relapsed/refractory solid tumor malignancies…
- Trial name
- NCT03323398
- Testing
- mRNA-2416, Durvalumab
- Where
- 9 sites in United States
- Volunteers
- 79 people
- Sponsor
- ModernaTX, Inc.
Non-muscle Invasive Bladder Cancer
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 combined with gemcitabine for patients who have BCG failure (defined as refractory, relapsing or intolerant), non-muscle invasive bladder…
- Trial name
- NCT01625260
- Testing
- ALT-801, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Altor BioScience
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12/human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human…
- Conditions
- Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma
- Trial name
- NCT03439085
- Testing
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab.
- Trial name
- NCT02384954
- Testing
- Rituximab, N-803
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Altor BioScience
Relapsed or Refractory Multiple Myeloma
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 in patients who have relapsed or refractory multiple myeloma.
- Trial name
- NCT01670994
- Testing
- ALT-801
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Altor BioScience
B-Lymphoid Malignancies, Acute Lymphocytic Leukemia
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
If you are reading and signing this form on behalf of a potential participant, please note: Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant.
- Conditions
- B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma
- Trial name
- NCT03056339
- Testing
- Fludarabine, Cyclophosphamide, Mesna
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer, Metastasis
Pembrolizumab + Idelalisib for Lung Cancer Study
This is a phase 1b/2 study to determine the safety and effectiveness of the combination of pembrolizumab and idelalisib in NSCLC patients whose disease has stopped responding to immune therapy.
- Conditions
- Non Small Cell Lung Cancer, Metastasis, Recurrence
- Trial name
- PIL (NCT03257722)
- Testing
- Pembrolizumab, Idelalisib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Asha Nayak
Endometrial Cancer, Endometrial Carcinosarcoma
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
This study will test the safety and efficacy of the experimental drug called durvalumab with or without another experimental drug called tremelimumab in endometrial cancer.
- Conditions
- Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma, Endometrial Cancer Recurrent
- Trial name
- NCT03015129
- Testing
- Durvalumab, Tremelimumab
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia
Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.
Stem cell transplant is an important therapeutic option for pediatric patients with relapsed or refractory leukemia. Although, full myeloablative transplants are widely used for patients with acute leukemia, myeloablative…
- Conditions
- Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia, Neoplasm Recurrent
- Trial name
- NCT01041508
- Testing
- Clofarabine, Total Body Irradiation, Stem Cell Transplantation
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
This study is a phase 1, dose finding, open-label study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT02658968
- Testing
- Betalutin
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Nordic Nanovector